

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical technologies evaluation programme

Equality impact assessment: Topic selection and scoping

MT359 3C Patch for treating diabetic foot ulcers

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

1. Have any potential equality issues been identified during the development of the topic briefing note or during selection, and, if so, what are they?

No equality issues were identified during topic selection.

It is noted in the scope that 3C Patch is intended for people with diabetes. In some cases, diabetes can be considered a disability. People of South Asian, African and African Caribbean family origin are more at risk of diabetes, however there is no evidence that the prevalence of diabetic foot ulceration and amputation is higher in these subgroups than in the general population of people with diabetes in the UK. Disability and race are protected characteristics under the 2010 Equalities Act.

Experts commenting during scoping on potential adoption issues noted that people who cannot provide the necessary 18 ml blood sample (for example, people with a fear of needles) would not be able to access treatment with 3C Patch. The experts did not identify any specific equalities issues in relation to this point.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

If appropriate, consideration will be given to characteristics that are shared by people with diabetic foot ulcer and are protected under equality legislation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No. The information about the prevalence of diabetes in protected groups was included as a special consideration in the draft for consultation and has been retained in the final scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders related to potential equality issues were identified during the scoping process.

Approved by Associate Director: Chris Chesters (acting AD)

Date: 4 March 2021